HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Different effects of AT1 receptor antagonist and ET(A) receptor antagonist on ischemia-induced norepinephrine release in rat hearts.

Abstract
Angiotensin type 1 receptor (AT1R) antagonist and endothelin type A receptor (ET(A)R) antagonist were compared as regards their effects on ischemia-induced exocytotic or carrier-mediated norepinephrine (NE) release from cardiac sympathetic nerve endings. According to the Langendorff technique, isolated rat hearts were subjected to 20-minute or 40-minute global ischemia followed by 30-minute reperfusion. Candesartan (selective AT1R antagonist) and ABT-627 (selective ET(A)R antagonist) were perfused, beginning 15 minutes before ischemia. Candesartan (10 and 100 nM) and ABT-627 (3 μM) suppressed excessive NE overflow (exocytotic release) in the coronary effluent from the heart exposed to 20-minute ischemia. In addition, these agents improved postischemic cardiac dysfunction. On the other hand, the beneficial effects of ABT-627 (1 and 3 μM) on NE overflow (carrier-mediated release) and cardiac dysfunction were also observed in 40-minute ischemia, whereas those were not improved by treatment with candesartan (10 and 100 nM and 1 μM). These findings suggest that both AT1R antagonist and ET(A)R antagonist have ability to inhibit the exocytotic NE release, but the carrier-mediated NE release induced by prolonged ischemia cannot be avoided by AT1R antagonist. Thus, ET(A)R antagonist may be more useful than AT1R antagonist in the clinical settings of ischemic heart disease.
AuthorsTaiki Fukumoto, Masashi Tawa, Kento Kitada, Naoto Yamashita, Mamoru Ohkita, Tomio Okamura, Yasuo Matsumura
JournalJournal of cardiovascular pharmacology (J Cardiovasc Pharmacol) Vol. 60 Issue 1 Pg. 55-60 (Jul 2012) ISSN: 1533-4023 [Electronic] United States
PMID22494993 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • Angiotensin II Type 1 Receptor Blockers
  • Benzimidazoles
  • Biphenyl Compounds
  • Endothelin A Receptor Antagonists
  • Pyrrolidines
  • Tetrazoles
  • candesartan
  • Atrasentan
  • Norepinephrine
Topics
  • Angiotensin II Type 1 Receptor Blockers (administration & dosage, pharmacology)
  • Animals
  • Atrasentan
  • Benzimidazoles (administration & dosage, pharmacology)
  • Biphenyl Compounds
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Endothelin A Receptor Antagonists
  • Male
  • Myocardial Ischemia (drug therapy, physiopathology)
  • Myocardial Reperfusion Injury (drug therapy, physiopathology)
  • Norepinephrine (metabolism)
  • Pyrrolidines (administration & dosage, pharmacology)
  • Rats
  • Rats, Sprague-Dawley
  • Tetrazoles (administration & dosage, pharmacology)
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: